Two curcumin analogs inhibited the function and protein expression of breast cancer resistance protein: in vitro and in vivo studies

References

• Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH. 1999. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res. 59(17):4237–4241.
   PubMed Web of Science ®Google Scholar
• Allen JD, Jackson SC, Schinkel AH. 2002. A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance. Cancer Res. 62(8):2294–2299.
   PubMed Web of Science ®Google Scholar
• Amawi H, Sim HM, Tiwari AK, Ambudkar SV, Shukla S. 2019. ABC transporter-mediated multidrug-resistant cancer. Adv Exp Med Biol. 1141:549–580. doi: 10.1007/978-981-13-7647-4_12.
   PubMed Web of Science ®Google Scholar
• Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. 2007. Bioavailability of curcumin: problems and promises. Mol Pharm. 4(6):807–818. doi: 10.1021/mp700113r.
   PubMed Web of Science ®Google Scholar
• Anuchapreeda S, Leechanachai P, Smith MM, Ambudkar SV, Limtrakul PN. 2002. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol. 64(4):573–582. doi: 10.1016/s0006-2952(02)01224-8.
   PubMed Web of Science ®Google Scholar
• Bircsak KM, Gupta V, Yuen PY, Gorczyca L, Weinberger BI, Vetrano AM, Aleksunes LM. 2016. Genetic and dietary regulation of glyburide efflux by the human placental breast cancer resistance protein transporter. J Pharmacol Exp Ther. 357(1):103–113. doi: 10.1124/jpet.115.230185.
   PubMed Web of Science ®Google Scholar
• Bironzo P, Di Maio M. 2018. A review of guidelines for lung cancer. J Thorac Dis. 10(Suppl 13):S1556–S1563. doi: 10.21037/jtd.2018.03.54.
   PubMed Web of Science ®Google Scholar
• Chearwae W, Shukla S, Limtrakul P, Ambudkar SV. 2006. Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. Mol Cancer Ther. 5(8):1995–2006. doi: 10.1158/1535-7163.MCT-06-0087.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Liang X, Hao J, Niu C, Lai Y. 2021. Application of a PBPK model to elucidate the changes of systemic and liver exposures for rosuvastatin, carotegrast, and bromfenac followed by OATP inhibition in monkeys. Clin Transl Sci. 14(5):1924–1934. doi: 10.1111/cts.13047.
   PubMed Web of Science ®Google Scholar
• Choi MK, Kim H, Han YH, Song IS, Shim CK. 2009. Involvement of Mrp2/MRP2 in the species different excretion route of benzylpenicillin between rat and human. Xenobiotica. 39(2):171–181. doi: 10.1080/00498250802642256.
   PubMed Web of Science ®Google Scholar
• Choi YH, Yu AM. 2014. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des. 20(5):793–807. doi: 10.2174/138161282005140214165212.
   PubMed Web of Science ®Google Scholar
• Dai CL, Liang YJ, Wang YS, Tiwari AK, Yan YY, Wang F, Chen ZS, Tong XZ, Fu LW. 2009. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Lett. 279(1):74–83. doi: 10.1016/j.canlet.2009.01.027.
   PubMed Web of Science ®Google Scholar
• Dei S, Braconi L, Romanelli MN, Teodori E. 2019. Recent advances in the search of BCRP- and dual P-gp/BCRP-based multidrug resistance modulators. Cancer Drug Resist. 2(3):710–743.
   PubMedGoogle Scholar
• Diah SK, Smitherman PK, Aldridge J, Volk EL, Schneider E, Townsend AJ, Morrow CS. 2001. Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins. Cancer Res. 61(14):5461–5467.
   PubMed Web of Science ®Google Scholar
• Ding XW, Wu JH, Jiang CP. 2010. ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci. 86(17–18):631–637. doi: 10.1016/j.lfs.2010.02.012.
   PubMed Web of Science ®Google Scholar
• Dong J, Qin Z, Zhang WD, Cheng G, Yehuda AG, Ashby CR, Jr., Chen ZS, Cheng XD, Qin JJ. 2020. Medicinal chemistry strategies to discover P-glycoprotein inhibitors: an update. Drug Resist Updat. 49:100681. doi: 10.1016/j.drup.2020.100681.
   PubMed Web of Science ®Google Scholar
• Galetti M, Petronini PG, Fumarola C, Cretella D, La Monica S, Bonelli M, Cavazzoni A, Saccani F, Caffarra C, Andreoli R, et al. 2015. Effect of ABCG2/BCRP expression on efflux and uptake of gefitinib in NSCLC cell lines. PLoS One. 10(11):e0141795. doi: 10.1371/journal.pone.0141795.
   PubMed Web of Science ®Google Scholar
• Gillet JP, Gottesman MM. 2010. Mechanisms of multidrug resistance in cancer. Methods Mol Biol. 596:47–76.
   PubMedGoogle Scholar
• Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, Sarkar S. 2014. Drug resistance in cancer: an overview. Cancers. 6(3):1769–1792. doi: 10.3390/cancers6031769.
   PubMed Web of Science ®Google Scholar
• Hsieh MT, Chang LC, Hung HY, Lin HY, Shih MH, Tsai CH, Kuo SC, Lee KH. 2017. New bis(hydroxymethyl) alkanoatecurcuminoid derivatives exhibit activity against triple-negative breast cancer in vitro and in vivo. Eur J Med Chem. 131:141–151. doi: 10.1016/j.ejmech.2017.03.006.
   PubMed Web of Science ®Google Scholar
• Huang L, Wang Y, Grimm S. 2006. ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos. 34(5):738–742. doi: 10.1124/dmd.105.007534.
   PubMed Web of Science ®Google Scholar
• Jandu H, Aluzaite K, Fogh L, Thrane SW, Noer JB, Proszek J, Do KN, Hansen SN, Damsgaard B, Nielsen SL, et al. 2016. Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines. BMC Cancer. 16(1):34. doi: 10.1186/s12885-016-2071-1.
   PubMedGoogle Scholar
• Jemnitz K, Veres Z, Tugyi R, Vereczkey L. 2010. Biliary efflux transporters involved in the clearance of rosuvastatin in sandwich culture of primary rat hepatocytes. Toxicol in Vitro. 24(2):605–610. doi: 10.1016/j.tiv.2009.10.009.
   PubMed Web of Science ®Google Scholar
• Kawahara H, Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y. 2010. Pharmacological interaction with sunitinib is abolished by a germ-line mutation (1291T > C) of BCRP/ABCG2 gene. Cancer Sci. 101(6):1493–1500. doi: 10.1111/j.1349-7006.2010.01539.x.
   PubMed Web of Science ®Google Scholar
• Kitamura S, Maeda K, Wang Y, Sugiyama Y. 2008. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 36(10):2014–2023. doi: 10.1124/dmd.108.021410.
   PubMed Web of Science ®Google Scholar
• Kukal S, Guin D, Rawat C, Bora S, Mishra MK, Sharma P, Paul PR, Kanojia N, Grewal GK, Kukreti S, et al. 2021. Multidrug efflux transporter ABCG2: expression and regulation. Cell Mol Life Sci. 78(21–22):6887–6939. doi: 10.1007/s00018-021-03901-y.
   PubMed Web of Science ®Google Scholar
• Kumar A, Jaitak V. 2019. Natural products as multidrug resistance modulators in cancer. Eur J Med Chem. 176:268–291. doi: 10.1016/j.ejmech.2019.05.027.
   PubMed Web of Science ®Google Scholar
• Lee CA, O'Connor MA, Ritchie TK, Galetin A, Cook JA, Ragueneau-Majlessi I, Ellens H, Feng B, Taub ME, Paine MF, et al. 2015. Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design. Drug Metab Dispos. 43(4):490–509. doi: 10.1124/dmd.114.062174.
   PubMed Web of Science ®Google Scholar
• Limtrakul P. 2007. Curcumin as chemosensitizer. Adv Exp Med Biol. 595:269–300. doi: 10.1007/978-0-387-46401-5_12.
   PubMed Web of Science ®Google Scholar
• Martin PD, Warwick MJ, Dane AL, Brindley C, Short T. 2003. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther. 25(10):2553–2563. doi: 10.1016/s0149-2918(03)80316-8.
   PubMed Web of Science ®Google Scholar
• Martin PD, Warwick MJ, Dane AL, Hill SJ, Giles PB, Phillips PJ, Lenz E. 2003. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther. 25(11):2822–2835. doi: 10.1016/s0149-2918(03)80336-3.
   PubMed Web of Science ®Google Scholar
• Mohamed MF, Coppola S, Feng T, Camp HS, Kim E, Othman AA. 2021. Effect of upadacitinib on the pharmacokinetics of rosuvastatin or atorvastatin in healthy subjects. Clin Pharmacol Drug Dev. 10(11):1335–1344. doi: 10.1002/cpdd.957.
   PubMed Web of Science ®Google Scholar
• Mohammad IS, He W, Yin L. 2018. Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR. Biomed Pharmacother. 100:335–348. doi: 10.1016/j.biopha.2018.02.038.
   PubMed Web of Science ®Google Scholar
• Moo TA, Sanford R, Dang C, Morrow M. 2018. Overview of breast cancer therapy. PET Clin. 13(3):339–354. doi: 10.1016/j.cpet.2018.02.006.
   PubMed Web of Science ®Google Scholar
• Nakanishi T, Shiozawa K, Hassel BA, Ross DD. 2006. Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood. 108(2):678–684. doi: 10.1182/blood-2005-10-4020.
   PubMed Web of Science ®Google Scholar
• Neerati P, Sudhakar YA, Kanwar JR. 2013. Curcumin regulates colon cancer by inhibiting P-glycoprotein in in-situ cancerous colon perfusion rat model. J Cancer Sci Ther. 5:313–319.
   PubMedGoogle Scholar
• Pfeifer ND, Bridges AS, Ferslew BC, Hardwick RN, Brouwer KL. 2013. Hepatic basolateral efflux contributes significantly to rosuvastatin disposition II: characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver. J Pharmacol Exp Ther. 347(3):737–745. doi: 10.1124/jpet.113.208314.
   PubMed Web of Science ®Google Scholar
• Pfeifer ND, Yang K, Brouwer KL. 2013. Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes. J Pharmacol Exp Ther. 347(3):727–736. doi: 10.1124/jpet.113.207472.
   PubMed Web of Science ®Google Scholar
• Qiao EQ, Yang HJ. 2014. Effect of pregnane X receptor expression on drug resistance in breast cancer. Oncol Lett. 7(4):1191–1196. doi: 10.3892/ol.2014.1817.
   PubMed Web of Science ®Google Scholar
• Sargent JM, Williamson CJ, Maliepaard M, Elgie AW, Scheper RJ, Taylor CG. 2001. Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia. Br J Haematol. 115(2):257–262. doi: 10.1046/j.1365-2141.2001.03122.x.
   PubMed Web of Science ®Google Scholar
• Sawangrat K, Yamashita S, Tanaka A, Morishita M, Kusamori K, Katsumi H, Sakane T, Yamamoto A. 2019. Modulation of intestinal transport and absorption of topotecan, a BCRP substrate, by various pharmaceutical excipients and their inhibitory mechanisms of BCRP transporter. J Pharm Sci. 108(3):1315–1325. doi: 10.1016/j.xphs.2018.10.043.
   PubMed Web of Science ®Google Scholar
• Scott LJ, Curran MP, Figgitt DP. 2004. Rosuvastatin: a review of its use in the management of dyslipidemia. Am J Cardiovasc Drugs. 4(2):117–138. doi: 10.2165/00129784-200404020-00005.
   PubMedGoogle Scholar
• Tan KP, Wang B, Yang M, Boutros PC, Macaulay J, Xu H, Chuang AI, Kosuge K, Yamamoto M, Takahashi S, et al. 2010. Aryl hydrocarbon receptor is a transcriptional activator of the human breast cancer resistance protein (BCRP/ABCG2). Mol Pharmacol. 78(2):175–185. doi: 10.1124/mol.110.065078.
   PubMed Web of Science ®Google Scholar
• Tornio A, Filppula AM, Niemi M, Backman JT. 2019. Clinical studies on drug-drug interactions involving metabolism and transport: methodology, pitfalls, and interpretation. Clin Pharmacol Ther. 105(6):1345–1361. doi: 10.1002/cpt.1435.
   PubMed Web of Science ®Google Scholar
• Twentyman PR, Luscombe M. 1987. A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer. 56(3):279–285. doi: 10.1038/bjc.1987.190.
   PubMed Web of Science ®Google Scholar
• Tyagi NK, Dhesy-Thind S. 2018. Clinical practice guidelines in breast cancer. Curr Oncol. 25(Suppl 1):S151–S160. doi: 10.3747/co.25.3729.
   PubMed Web of Science ®Google Scholar
• Uchida M, Tajima Y, Kakuni M, Kageyama Y, Okada T, Sakurada E, Tateno C, Hayashi R. 2018. Organic anion-transporting polypeptide (OATP)-mediated drug-drug interaction study between rosuvastatin and cyclosporine A in chimeric mice with humanized liver. Drug Metab Dispos. 46(1):11–19. doi: 10.1124/dmd.117.075994.
   PubMed Web of Science ®Google Scholar
• Wang X, Sykes DB, Miller DS. 2010. Constitutive androstane receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. Mol Pharmacol. 78(3):376–383. doi: 10.1124/mol.110.063685.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang H, Chen X. 2019. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2(2):141–160.
   PubMedGoogle Scholar
• Westover D, Li F. 2015. New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies. J Exp Clin Cancer Res. 34(1):159. doi: 10.1186/s13046-015-0275-x.
   PubMedGoogle Scholar
• Yang JJ, Milton MN, Yu S, Liao M, Liu N, Wu JT, Gan L, Balani SK, Lee FW, Prakash S, et al. 2010. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor. Drug Metab Lett. 4(4):201–212.
   PubMedGoogle Scholar
• Yang KY, Lin LC, Tseng TY, Wang SC, Tsai TH. 2007. Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 853(1–2):183–189. doi: 10.1016/j.jchromb.2007.03.010.
   PubMed Web of Science ®Google Scholar
• Yu CP, Hsieh YC, Shia CS, Hsu PW, Chen JY, Hou YC, Hsieh YW. 2016. Increased systemic exposure of methotrexate by a polyphenol-rich herb via modulation on efflux transporters multidrug resistance-associated protein 2 and breast cancer resistance protein. J Pharm Sci. 105(1):343–349. doi: 10.1016/j.xphs.2015.11.031.
   PubMed Web of Science ®Google Scholar
• Zhang W, Fan YF, Cai CY, Wang JQ, Teng QX, Lei ZN, Zeng L, Gupta P, Chen ZS. 2018. Olmutinib (BI1482694/HM61713), a novel epidermal growth factor receptor tyrosine kinase inhibitor, reverses ABCG2-mediated multidrug resistance in cancer cells. Front Pharmacol. 9:1097. doi: 10.3389/fphar.2018.01097.
   PubMed Web of Science ®Google Scholar
• Zhou X, Zhang F, Chen C, Guo Z, Liu J, Yu J, Xu Y, Zhong D, Jiang H. 2017. Impact of curcumin on the pharmacokinetics of rosuvastatin in rats and dogs based on the conjugated metabolites. Xenobiotica. 47(3):267–275. doi: 10.1080/00498254.2016.1183060.
   PubMed Web of Science ®Google Scholar